API Consumer Brands

Supply issue Active

API Consumer Brands has decided to close its Auckland manufacturing plant and withdraw from the New Zealand pharmaceutical market.

API in New Zealand

API have notified the Australian Stock Exchange of their decision to focus on their retail and distribution businesses.

We can assure people that there is no issue with the current supply of API’s publicly funded products.

Products currently supplied by API

Chemical Presentation Brand Pharmacode
Citalopram hydrobromide Tab 20 mg PSM Citalopram 2479621
Codeine phosphate Tab 15 mg PSM 206717
Codeine phosphate Tab 30 mg PSM 206733
Codeine phosphate Tab 60 mg PSM 206776
Dexamfetamine sulfate Tab 5 mg PSM 2461374
Domperidone Tab 10 mg Pharmacy Health 2549093
Glycerol Suppos 3.6 g PSM 778338
Hydrocortisone Crm 1% Hydrocortisone (PSM) 277002
Hydrocortisone Crm 1% Hydrocortisone (PSM) 2580462
Isoniazid Tab 100 mg PSM 267473
Methadone hydrochloride Tab 5 mg Methatabs 2565277
Oxytocin with ergometrine maleate Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml Syntometrine 256269
Paracetamol Oral liq 120 mg per 5 ml Paracare 304905
Paracetamol Oral liq 250 mg per 5 ml Paracare Double Strength 306088
Permethrin Crm 5% Lyderm 479233
Pethidine hydrochloride Tab 50 mg PSM 259942
Phenobarbitone Tab 15 mg PSM 765481
Phenobarbitone Tab 30 mg PSM 439886
Prochlorperazine Tab 3 mg buccal Buccastem 340537
Sodium fluoride Tab 1.1 mg (0.5 mg elemental) PSM 358827

Pharmac's response

We will be working closely with API to manage their exit from the New Zealand pharmaceutical market. We will need to do this on a case-by-case basis. This ensures our approach is the right one for each medicine.

We have issued a Future Procurement Opportunity (FPO) on the Government Electronic Tenders Service (GETS). One of the many options we're considering is issuing a competitive procurement process to secure alternative products. Suppliers interested in supplying these markets should register with GETS and subscribe to the FPO for more information. We welcome early feedback from suppliers to help plan our approach.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz